Hasil Pencarian - Cyril Abdeddaim

  • Menampilkan 1 - 3 hasil dari 3
Perbaiki Hasil
  1. 1
    Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

    Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group oleh Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

    Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group oleh Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer

    The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer oleh François Cherifi, François Cherifi, Sophie Lefevre Arbogast, Sophie Lefevre Arbogast, Jonaz Font, Cyril Abdeddaim, Stephanie Becourt, Nicolas Penel, Elodie Coquan, Elodie Coquan, Justine Lequesne, Yori Gidron, Florence Joly, Florence Joly

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: